While Botox and Biogen may seenlike strange bedfellows,Biogen's multiple sclerosis franchise hassome strategic overlap with Allergan's central nervous system franchise. In addition,while this would be a massivedeal,(Cowen'sresearch team ballparks it at$100 billion), they alsoestimate it couldadd$11 billion to Allergan's 2017 annual revenue. Biogen could also end up the hunter instead of the hunted. Its $4.5 billioncash store gives it options, including buying another biotech or drugmaker. "Eat or be eaten" is the rule in the healthcare space these days, and Biogen is a stock I believecould face big changes ahead.